These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 28624906)

  • 1. Pathogen reduction/inactivation of products for the treatment of bleeding disorders: what are the processes and what should we say to patients?
    Di Minno G; Navarro D; Perno CF; Canaro M; Gürtler L; Ironside JW; Eichler H; Tiede A
    Ann Hematol; 2017 Aug; 96(8):1253-1270. PubMed ID: 28624906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathogen inactivation and removal methods for plasma-derived clotting factor concentrates.
    Klamroth R; Gröner A; Simon TL
    Transfusion; 2014 May; 54(5):1406-17. PubMed ID: 24117799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Universal implementation of pathogen inactivation in labile blood products is a major step towards transfusion safety].
    Cazenave JP
    Bull Acad Natl Med; 2010 Dec; 194(9):1707-19; discussion 1719-20. PubMed ID: 22043595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prevention of bacterial risk: pathogen inactivation/detection of bacteria].
    Morel P; Naegelen C; Deschaseaux M; Bardiaux L
    Transfus Clin Biol; 2013 May; 20(2):109-14. PubMed ID: 23622837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Towards pathogen inactivation of red blood cells and whole blood targeting viral DNA/RNA: design, technologies, and future prospects for developing countries.
    Drew VJ; Barro L; Seghatchian J; Burnouf T
    Blood Transfus; 2017 Oct; 15(6):512-521. PubMed ID: 28488960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogen inactivation: coming of age.
    Lozano M; Cid J
    Curr Opin Hematol; 2013 Nov; 20(6):540-5. PubMed ID: 24104416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current debate on pathogen inactivation of platelet concentrates--to use or not to use?
    Hervig T; Seghatchian J; Apelseth TO
    Transfus Apher Sci; 2010 Dec; 43(3):411-414. PubMed ID: 21075686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood-Borne Pathogens: A Canadian Blood Services Centre for Innovation Symposium.
    Walsh GM; Shih AW; Solh Z; Golder M; Schubert P; Fearon M; Sheffield WP
    Transfus Med Rev; 2016 Apr; 30(2):53-68. PubMed ID: 26962008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current concepts in the prevention of pathogen transmission via blood/plasma-derived products for bleeding disorders.
    Di Minno G; Perno CF; Tiede A; Navarro D; Canaro M; Güertler L; Ironside JW
    Blood Rev; 2016 Jan; 30(1):35-48. PubMed ID: 26381318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Single-donor (apheresis) platelets and pooled whole-blood-derived platelets--significance and assessment of both blood products].
    Hitzler WE
    Clin Lab; 2014; 60(4):S1-39. PubMed ID: 24779310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on pathogen inactivation treatment of plasma, with the INTERCEPT Blood System: Current position on methodological, clinical and regulatory aspects.
    Irsch J; Seghatchian J
    Transfus Apher Sci; 2015 Apr; 52(2):240-4. PubMed ID: 25824703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Component pathogen inactivation: a critical review.
    Prowse CV
    Vox Sang; 2013 Apr; 104(3):183-99. PubMed ID: 23134556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Critical issues in hematology: anemia, thrombocytopenia, coagulopathy, and blood product transfusions in critically ill patients.
    Drews RE
    Clin Chest Med; 2003 Dec; 24(4):607-22. PubMed ID: 14710693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of pathogen inactivation on the storage lesion in red cells and platelet concentrates.
    Seghatchian J; Hervig T; Putter JS
    Transfus Apher Sci; 2011 Aug; 45(1):75-84. PubMed ID: 21782517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogen Inactivation Technologies: The Advent of Pathogen-Reduced Blood Components to Reduce Blood Safety Risk.
    Devine DV; Schubert P
    Hematol Oncol Clin North Am; 2016 Jun; 30(3):609-17. PubMed ID: 27112999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogen reduced plasma products: a clinical practice scientific review from the AABB.
    Cushing MM; Pagano MB; Jacobson J; Schwartz J; Grossman BJ; Kleinman S; Han MA; Cohn CS;
    Transfusion; 2019 Sep; 59(9):2974-2988. PubMed ID: 31268584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogen Reduction: The State of the Science in 2019.
    Gehrie EA; Rutter SJ; Snyder EL
    Hematol Oncol Clin North Am; 2019 Oct; 33(5):749-766. PubMed ID: 31466602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathogen safety of long-term treatments for bleeding disorders: still relevant to current practice.
    Di Minno G; Canaro M; Ironside JW; Navarro D; Perno CF; Tiede A; Gürtler L
    Haematologica; 2013 Oct; 98(10):1495-8. PubMed ID: 24091928
    [No Abstract]   [Full Text] [Related]  

  • 19. Pathogen inactivation: emerging indications.
    Kleinman S
    Curr Opin Hematol; 2015 Nov; 22(6):547-53. PubMed ID: 26390164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogen safety of long-term treatments for bleeding disorders: (un)predictable risks and evolving threats.
    Di Minno G; Canaro M; Ironside JW; Navarro D; Perno CF; Tiede A; Guertler L
    Semin Thromb Hemost; 2013 Oct; 39(7):779-93. PubMed ID: 24030344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.